<DOC>
	<DOCNO>NCT00335478</DOCNO>
	<brief_summary>RATIONALE : Antibiotics , daptomycin , may control neutropenia , fever , infection patient cancer . PURPOSE : This phase II trial study well daptomycin work treat neutropenia fever patient cancer .</brief_summary>
	<brief_title>Daptomycin Treating Neutropenia Fever Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess response rate therapy within 72 hour start daptomycin cancer patient neutropenic fever . Secondary - Assess percentage bacterial cure patient document gram-positive bacterial infection . - Assess time afebrile state . - Assess pharmacokinetic data daptomycin neutropenic patient . - Document incidence breakthrough infection require change therapy additional agent clear . - Assess tolerability daptomycin neutropenic patient . - Assess document adverse event toxicity due daptomycin . OUTLINE : This open-label , pilot study . Patients first receive standard treatment gram-negative bacteria 72 hour . If patient still febrile 72 hour , daptomycin administer . Patients receive daptomycin IV 30 minute daily . Patients afebrile , neutropenic ( absolute neutrophil count [ ANC ] &gt; 500/mm³ ) , sign infection 72 hour therapy may discontinue daptomycin . Patients afebrile neutropenic ( ANC &lt; 500/mm³ ) 72 hour therapy continue receive daptomycin absolute neutrophil count ( ANC ) &gt; 500/mm³ 2 consecutive day . Patients febrile without continue neutropenia ( ANC &lt; 500/mm³ ) 72 hour therapy continue receive daptomycin 10-14 day absence unacceptable toxicity . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer Diagnosis neutropenic fever Temperature &gt; 38.3°C OR ≥ 38°C twice within 12 hour Absolute neutrophil count &lt; 500/mm^³ ≥ 1 following : Mucositis Concurrent skin soft tissue infection Indwelling catheter and/or suspect catheter infection Recent quinolone prophylaxis Positive blood culture grampositive cocci final identification document grampositive pathogen Colonization βlactam resistant grampositive organism ( commonly nares skin ) Hypotension , tachycardia , narrow pulse pressure , tachypnea , sign cardiovascular compromise Expected duration neutropenia ≥ 3 day No known infection daptomycinresistant organism gramnegative organism yet meet criterion addition grampositive antimicrobial therapy No suspect meningitis osteomyelitis No document suspect grampositive pneumonia No suspect proven endocarditis PATIENT CHARACTERISTICS : Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy ≥ 2 week Creatinine clearance ≥ 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception No known sensitivity daptomycin product excipients No history concurrent rhabdomyolysis No HIV positivity No psychiatric disorder would preclude study compliance No sign symptoms myopathy creatine phosphokinase ( CPK ) elevation &gt; 1,000 U/L ( 5 time upper limit normal [ ULN ] ) No CPK elevation &gt; 10 time ULN patient sign symptom myopathy PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 7 day since prior daptomycin antibiotic agent cover grampositive organism No concurrent hemodialysis continuous ambulatory peritoneal dialysis No concurrent succinylcholine , ethanol , fludrocortisone , olanzapine , pioglitazone No concurrent hydroxymethyl glutaryl ( HMG ) coenzyme A ( HMG CoA ) reductase inhibitor ( e.g. , lovastatin , simvastatin , atorvastatin ) Concurrent therapy gramnegative bacterial infection allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>neutropenia</keyword>
	<keyword>infection</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>fever , sweat , hot flash</keyword>
</DOC>